Cancer Treatment Beyond Chemotherapy: A Guide to Modern Modalities

Modern oncology offers diverse treatment modalities beyond traditional cytotoxic chemotherapy. Selection depends on cancer type, stage, biomarkers, and patient factors.

Major Treatment Modalities

1. Targeted Therapy

• Drugs against specific molecular drivers: EGFR, ALK, HER2, BCR-ABL, BRAF, PARP, CDK4/6, BTK
• Examples: imatinib (CML), osimertinib (EGFR+ NSCLC), trastuzumab (HER2+ breast), olaparib (BRCA+ ovarian)
• Biomarker-driven; oral or IV; resistance inevitably develops

2. Immunotherapy

• Checkpoint inhibitors: Anti-PD-1/PD-L1 (pembrolizumab, nivolumab), anti-CTLA-4 (ipilimumab)—release T-cell brakes
• CAR-T: Autologous T-cells engineered against CD19 (B-ALL, DLBCL), BCMA (myeloma)
• Bispecific antibodies: Blinatumomab (CD3×CD19), teclistamab (CD3×BCMA)
• Cancer vaccines, oncolytic viruses (T-VEC): Emerging approaches

3. Radiation Therapy

• EBRT (IMRT, VMAT, SBRT/SABR), brachytherapy, proton therapy
• Curative (definitive), adjuvant, palliative (bone, brain mets)
• Hypofractionation: fewer, higher doses (convenience, radiobiological advantage)

4. Surgery

• Primary resection (curative for localized disease)
• Minimally invasive (laparoscopic, robotic) → less morbidity
• Organ preservation (breast-conserving, sphincter-sparing)
• Cytoreductive + HIPEC (peritoneal metastases)

5. Hormonal/Endocrine Therapy

• Breast: SERMs (tamoxifen), AIs (letrozole), SERDs (fulvestrant), CDK4/6 inhibitors
• Prostate: ADT (GnRH agonists/antagonists), ARSI (enzalutamide, abiraterone, darolutamide)
• Thyroid: TSH suppression (levothyroxine)

6. Cellular Therapy

• Autologous/allogeneic HSCT (leukemia, lymphoma, myeloma)
• CAR-T (see immunotherapy)
• TIL therapy (melanoma, cervical cancer)

7. Ablative Techniques

• RFA, MWA, cryoablation (liver, kidney, lung, bone metastases)
• Image-guided; minimally invasive

8. Emerging Therapies

• Epigenetic therapy (azacitidine, HDAC inhibitors)
• Antibody-drug conjugates (T-DXd, sacituzumab govitecan, enfortumab vedotin)
• KRAS G12C inhibitors (sotorasib, adagrasib)
• Radiopharmaceuticals (Lu-177 PSMA, Lu-177 DOTATATE)

Personalized Selection

Molecular profiling (NGS, IHC, FISH) + multidisciplinary tumor board → matched therapy. Clinical trials remain essential for advancing options.